CYTK — Cytokinetics, Incorporated
Healthcare · ETF XLV · as of 2026-09-21
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Cytokinetics, Incorporated
NMS
Healthcare · Biotechnology
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Price & today
$67.56
ATR(14) 2.57 (3.81%)
| Stock today | -1.77% |
| Sector ETF today | +0.37% |
| Residual (stock-specific) | -2.14% |
Sector correlation
| 20-day correlation with XLV | -0.17 |
| 60-day correlation with XLV | 0.07 |
| Status | DECOUPLING |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $70.61 |
| 20 EMA | $72.38 |
| 50 EMA | $74.75 |
| EMA stack | BEARISH |
| RSI(14) | 32.7 |
| 52-week high distance | -23.50% |
| 52-week low distance | +105.41% |
Signals
| Market F&G | 45.1 |
| Bull% | 12.9% |
| OVTLYR status | SELL (46d) |
| Sector rank | #94 |
| Next earnings | 2026-11-03 (TNS, 42d) |
MarketSmith metrics - our compute
RS Rating
12.4
ADR%
3.4
RMV (tight)
9.0
Ext (ATR>20EMA)
-1.9
Rel Vol
87.0%
U/D 50d
0.70
U/D 25d
0.79
Accum/Dist 25d
1 / 4
EPS YoY
-34.0%
LoD dist
8.0
Off 52w High
23.5%
Above 52w Low
43.1%
1W / 1M
-6.7 / -12.5
Avg $Vol 50d
140.6M
Mkt Cap (B)
9.2
Trend 8/8
no
Sector XLV
+0.8% 1W
Base len (VCP)
6wk (6/21)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
-
Fwd P/E
-
PEG
-
Price/Book
-12.3
Profit margin
0.0%
ROE
-
Debt/Equity
-
Rev growth
-57.1%
Analyst target
$109 (+61%)
Analyst rating
STRONG_BUY
Institutional %
120.9%
Insider %
0.7%
Float %
99.3%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
91 / 146
Industry
Biotechnology
Float
134.9M
Float turnover 20d
1.4%
Avg $Vol 20d / 50d
141.4M / 140.6M
Days to cover
6.6
Short % float
19.4%
Institutional %
120.9%
Weinstein stage
1
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | -1.36 | - | 0.5 | +22% |
| Feb-25 | -1.26 | - | 16.9 | +912% |
| May-25 | -1.36 | - | 1.6 | +89% |
| Aug-25 | -1.12 | - | 66.8 | +26715% |
| Nov-25 | -1.54 | - | 1.9 | +318% |
| Feb-26 | -1.50 | - | 17.8 | +5% |
| May-26 | -1.67 | - | 19.4 | +1126% |
| Aug-26 | -1.50 | - | 28.6 | -57% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 18 · AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
- Sep 04 + Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? Zacks Investment Research
- Sep 02 + Cytokinetics to Participate in September Investor Conferences GlobeNewswire Inc.
- Sep 02 + Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? Zacks Investment Research
- Aug 29 + Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 GlobeNewswire Inc.
- Aug 22 + Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 The Motley Fool
- Aug 06 · Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
- Aug 06 · Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates Yahoo